Eli Lilly

News

Data cues up AZ oral SERD filing in first-line breast cancer

AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.

News

Lilly launches discounted high-strength Zepbound vials in US

Eli Lilly's drive to provide as many treatment options as possible for its obesity drug Zepbound has continued with the launch of new high-dose vials.

News

Black and white image of a child holding a conch to their ear

Evidence builds behind Regeneron's deafness gene therapy

Ten out of 11 children with congenital deafness treated with a gene therapy developed by Regeneron have seen "notable" improvements in hearing.

News

Small study finds GLP-1 drug can curb excess alcohol use

Novo Nordisk's GLP-1 receptor agonist semaglutide has been shown to help people struggling with alcohol use disorder.

News

High-dose semaglutide ramps up weight loss, says Novo

Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.

News

Lilly nets a second FDA okay for Omvoh, in Crohn's disease

Eli Lilly picks up a second FDA approval for IL-23 inhibitor Omvoh in Crohn's disease, but will it kickstart sales growth?

Data cues up AZ oral SERD filing in first-line breast cancer

Lilly launches discounted high-strength Zepbound vials in US

Evidence builds behind Regeneron's deafness gene therapy

Small study finds GLP-1 drug can curb excess alcohol use

High-dose semaglutide ramps up weight loss, says Novo

Lilly nets a second FDA okay for Omvoh, in Crohn's disease

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Eli Lilly

Editor's Picks